Intelerad Medical Systems Incorporated appears in FDA device enforcement records as the recalling firm for IntelePACS software, identified in one filing as “System, Image Processing, Radiological.” The two records reviewed here are Class II recalls with ongoing status, both initiated in September 2026 and classified in October and November 2026. Intelerad’s published product documentation separately describes IntelePACS as cloud-oriented image access software that integrates with existing infrastructure, and its conformance and integration statements address DICOM, HL7 and IHE interfaces. The company’s product pages state that Intelerad is now a GE HealthCare company; that statement is the publisher’s own and is not treated here as an independently verified ownership record. [1][2][5][6][7][10]
The FDA recall records and their scope
Recall Z-0357-2027 covers IntelePACS software across a long list of affected version ranges, from PACS-4-3-4-R20 and PACS-4-9-1-R80 through PACS-5-9-1-R8 through R19, with a stated product quantity of 560 software platforms. FDA lists the reason as a cybersecurity vulnerability that could allow a malicious user to take over an administrator session, delete or modify image or study data, or lock legitimate users out of the system, plus a software issue that may result in unintended deletion of image data from an external archive integration. The action is recorded as voluntary and firm initiated, with e-mail as the initial notification method. [1]
Recall Z-0186-2027 names IntelePACS and InteleConnect Portal/Tech Portal together, with affected versions spanning PACS-5-1-1-R102, PACS-5-2-1-R93, PACS-5-3-1-R83 through R128, PACS-5-4-1-R66 through R101, PACS-5-5-1-R50 through R89, PACS-5-6-1-R41 through R81, PACS-5-7-1-R21 through R61, PACS-5-8-1-R2 through R42, and PACS-5-9-1-R8 through R19. FDA records nationwide US distribution for this filing, an initiation date of 5 September 2026, e-mail notification, and a center classification date of 15 October 2026. [2]
Both filings list Montreal, Canada as the city on the FDA record and carry ongoing status. The FDA record address is a filing detail, not a statement of corporate headquarters. The two records are separate enforcement entries with distinct recall numbers, event identifiers and classification dates, and neither record states a total installed base or safety performance measure for the company. [1][2]
Documented product and interface documentation
Intelerad publishes an IntelePACS DICOM Conformance Statement covering version 4.11.1 and later, copyrighted 2004–2026, which describes reporting problems to Intelerad Technical Support with details such as client code, installation location, error messages, AE Titles and operating systems. A separate IntelePACS IHE Integration Statement covers the same 4.11.1-and-later version line and lists regional support telephone contacts, including North American, UK, Ireland, Australian and New Zealand numbers. [5][8]
An IntelePACS HL7 Integration Guide covers version 4.12.1 and later and references DICOM systems in its scope. These documents are manufacturer-published technical statements about interface conformance and support channels; they do not report clinical performance, customer counts or certification outcomes. [10]
Product positioning as published by Intelerad
Intelerad’s IntelePACS product pages describe the software as delivering cloud-first, scalable, high-performance image access that integrates with existing infrastructure and lets radiologists read anytime, from anywhere. The pages describe imaging as shaped by five core pillars: the imaging hub, comprehensive diagnostic viewing, autonomy and flexibility, cloud-enabled infrastructure, and augmented intelligence. A separate Intelerad page frames IntelePACS as enterprise imaging built to perform at scale and refers to reducing total cost of ownership for hospitals, health systems and radiology groups. [6][7][9]
The same product pages state that Intelerad is now a GE HealthCare company and link to a page about the two organizations coming together. That relationship is reported as the publisher’s statement; the FDA enforcement records name Intelerad Medical Systems Incorporated as the recalling firm and do not address ownership. [1][6][9]
What the record set does and does not establish
The linked portfolio snapshot for this company contains no records by pathway and no decision counts, so the two recall entries are the documented regulatory record available here rather than a measure of total filings, sales or portfolio breadth. Both are Class II, both are ongoing, and both concern software version ranges rather than a single device unit. [1][2]
FDA database pages for the two recalls confirm the Class 2 device recall designation and provide the agency’s standard database navigation and contact information. They add no product claims beyond the enforcement entries. Details such as the number of affected customers, remediation completion, or the technical root cause beyond the stated reasons are not established by these sources. [3][4]




